VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced it has been selected as the winner of the “Predictive Analytics Solution of the Year” in this year’s BioTech Breakthrough Awards program conducted by BioTech Breakthrough. Biotech Breakthrough is a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.
VeriSIM Life was recognized for its first-in-class “virtual drug development engine”, BIOiSIM, which combines artificial intelligence and machine learning with mechanistic modeling to make early and accurate predictions about compound safety and efficacy. This combined discovery and translational engine allows pharmaceutical researchers to preflight advancements in medicine in a fraction of the time and cost it takes today and provides far better patient outcomes.
“We are honored to receive this award from BioTech Breakthrough,” said Dr. Jo Varshney, CEO of VeriSIM Life. “Being named Predictive Analytics Solution of the Year validates our recent BIOiSIM platform innovations. Technologies like our unique Translational Index™, which synthesizes the potential for clinical success of any drug candidate, enable smarter decisions about how to advance asset programs and ultimately improve the lives of patients in need.”
Earlier this year, VeriSIM was awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to fund the AI-driven development of medications for substance use disorder (SUD). The company is also co-developing new drugs with Mayo Clinic in key disease areas, including oncology, hematology, bone/joint disorders, and neurological diseases.
“VeriSIM Life is empowering researchers to make decisions faster by providing meaningful insights much earlier in the drug development process with unprecedented accuracy and scalability,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “VeriSIM Life clearly stood out as a top innovator in the Biotech Breakthrough community of candidate companies for this award, and we will look to them to continue to deliver innovative solutions that further the productivity and performance in the drug discovery and research space. Congratulations on being our choice for the Predictive Analytics Solution of the Year.”
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top technology companies, solutions, and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,350 nominations from over a dozen countries.
For more information about VeriSIM Life, follow them on Twitter @VeriSIMlife, visit www.verisimlife.com or email press@verisimlife.com.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com
About VeriSIM Life
VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by significantly reducing the time and money it takes to bring a drug to market. BIOiSIM™ is a first-in-class ‘virtual drug development engine’ that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. The program reduces the time and cost of drug discovery and development and dramatically reduces the need for animal testing that, in the vast majority of cases, does not translate to humans. For more information, visit www.verisimlife.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005242/en/